PTCTPTCTHealthcare · Biotechnology

PTCT Stock Forecast: PTC Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$60
−1.00% on the day

The 15 Wall Street analysts covering PTC Therapeutics, Inc. hold a median 12-month price target of $98 — +62.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$5.1B
Ticker Nerd rank
64/ 100
Median analyst target
$98
Analysts covering
15
Revenue$360.5M+101.5% y/y
Operating income$149.0M
Net income$83.5M
Free cash flow$122.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
+1.9%
YTD
−20.5%
1Y
−20.2%
From 52W high
−32.6%
From 52W low
+1.9%
$59
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PTC Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
64/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
95
Volatility
77
Revisions
67
Accruals
61
Momentum
61
Size
23
Growth
19
Issuance
19

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PTCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26PTCTHigh $137Median $98Low $62

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
13 Buy2 Hold0 Sell
Low $62Median $98High $137

The green dot is the last close — the median target sits +62.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
2 Nov 2026CitigroupMaintainsBuy$108 → $109
30 Oct 2026RBC CapitalMaintainsSector Perform$75 → $77
30 Oct 2026TD CowenMaintainsBuy$90 → $95
30 Oct 2026Wells FargoMaintainsOverweight$109 → $112
15 Oct 2026UBSAssumesBuy$80 → $90
8 Oct 2026RBC CapitalMaintainsSector Perform—
8 Oct 2026RBC CapitalMaintainsSector Perform$85 → $75
22 Sept 2026Cantor FitzgeraldMaintainsOverweight—
22 Sept 2026Cantor FitzgeraldMaintainsOverweight$130 → $137
14 Sept 2026Leerink PartnersAssumesOutperform$98
14 Aug 2026BarclaysMaintainsOverweight—
14 Aug 2026BarclaysMaintainsOverweight$120 → $122
13 Aug 2026Wells FargoMaintainsOverweight—
13 Aug 2026Wells FargoMaintainsOverweight$106 → $109
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Morgan StanleyMaintainsOverweight$93 → $104
31 July 2026Wells FargoMaintainsOverweight$93 → $106
31 July 2026Wells FargoMaintainsOverweight—
20 July 2026Wells FargoMaintainsOverweight$95 → $93
20 July 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PTCT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PTCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, PTC Therapeutics, Inc. returned −20.2% against +11.2% for the S&P 500, dividends included.

PTCT vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26PTCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−41.4%
Analysts raising
0
Analysts cutting
1
Fundamentals

PTC Therapeutics, Inc. (PTCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.5×

Cheaper than 63% of US stocks

Price / sales
4.4×

Cheaper than 26% of US stocks

Price / book
−30.6×

Cheaper than 99% of US stocks

EV / EBITDA
19.1×

Cheaper than 15% of US stocks

Growth & margins
Revenue growth (YoY)
69.6%

Higher than 89% of US stocks

Earnings growth (YoY)
101.5%

Higher than 84% of US stocks

Gross margin
94.5%

Higher than 98% of US stocks

Operating margin
21.5%

Higher than 82% of US stocks

Net margin
−9.2%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−332.5%

Higher than 4% of US stocks

Return on assets
5.3%

Higher than 77% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PTC Therapeutics, Inc. (PTCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PTC Therapeutics, Inc. has a market value of $5.1B and an enterprise value of $5.9B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 69.6% year on year.

  • Net income over the same four quarters: −$38.4M, a −3.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.58.

  • Free cash flow in the twelve months to 30 June 2026: −$332.6M.

  • Shares outstanding: 83.3M.

  • Trailing P/E: 7.5×; forward P/E: 19.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • PTC Therapeutics, Inc. employs 991 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

PTCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTCTPTC Therapeutics, Inc.$5.1B64
ERASErasca, Inc.$5.2B48
DNTHDianthus Therapeutics, Inc.$4.9B77
MANEVeradermics, Inc.$5.3B5
SRRKScholar Rock Holding Corp.$5.4B47
COGTCogent Biosciences, Inc.$4.7B33
EWTXEdgewise Therapeutics, Inc.$4.7B69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PTC Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTCT news & analysis

PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

MarketBeat · 17 Nov 2026positive

PTC Therapeutics expects to provide 2027 sales guidance for Sephience in January. Executives are seeking to show that the drug’s strong first year of sales can be sustained, amid discussion of potential exceeding $2 billion.

Why it matters — The upcoming guidance will give PTCT watchers information about the company’s expectations for Sephience’s sales trajectory.

PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

Seeking Alpha · 3 Nov 2026negative

Seeking Alpha rates PTC Therapeutics Hold, bordering on Sell, estimating fair value at $52 per share versus a current price of $59.97. Sephience's strong launch and repeated sales beats against conservative guidance are offset by declines in legacy products, with Q4 and 2027 results identified as key inflection points.

Why it matters — PTCT watchers may focus on whether Sephience's growth can offset legacy product declines as the company approaches the cited Q4 and 2027 milestones.

PTC Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire · 2 Nov 2026neutral

PTC Therapeutics announced that its executives will speak at the Jefferies Global Healthcare Conference on Nov. 16 at 11 a.m.

Why it matters — The conference appearance is an opportunity for investors following PTCT to hear from company executives.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 30 Oct 2026neutral

PTC Therapeutics announced inducement grants approved Oct. 28, 2026, for 13 new employees: stock options covering an aggregate of 9,620 common shares and 11,535 restricted stock units, each convertible into one share upon vesting.

Why it matters — The grants are compensation awards to new employees and represent potential future share issuance upon option exercise or RSU vesting.

FAQ

Frequently asked questions about PTCT stock

What is the PTCT stock price forecast for 2026-2027?

The 15 Wall Street analysts covering PTC Therapeutics, Inc. have a median 12-month price target of $98, with estimates ranging from $62 to $137. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTCT stock a buy right now?

Of the 15 analysts covering PTC Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PTC Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTCT?

As at 16 Nov 2026, PTC Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will PTCT stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +62.4% from the last close, and Ticker Nerd's factor model ranks PTC Therapeutics, Inc. 64 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTCT stock forecast for 2030?

No analyst covering PTC Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $137 over the next 12 months.

How has PTCT stock performed over the past year?

PTC Therapeutics, Inc. returned -20.2% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders.

What is the latest news on PTCT?

The most recent item we track (MarketBeat, 17 Nov 2026): "PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date". PTC Therapeutics expects to provide 2027 sales guidance for Sephience in January. Executives are seeking to show that the drug’s strong first year of sales can be sustained, amid discussion of potential exceeding $2 billion.

Company

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders. Its current portfolio includes treatments for conditions such as Duchenne muscular dystrophy, phenylketonuria, and aromatic L-amino acid decarboxylase deficiency, along with other rare neurological and metabolic diseases. The company also works on gene therapy and small-molecule programs designed to address serious unmet medical needs. PTC Therapeutics serves children and adults in the United States and international markets, and its commercial offerings are supported by a research and development pipeline aimed at expanding its rare disease franchise. Headquartered in Warren, New Jersey, PTC Therapeutics plays a specialized role in the biopharmaceutical market by concentrating on niche therapies for complex, underserved patient populations.

CEO Dr. Matthew B. Klein F.A.C.S., M.D., M.S. · 991 employees · United States · https://www.ptcbio.com